ESMO 23: Concerns Despite Unprecedented Early-Stage Lung Cancer Win For Roche’s Alecensa

The Swiss group's ALK inhibitor Alecensa improved disease-free survival by 76% in early-stage patients with the mutation, a first for the class, but an ESMO discussant raises questions about toxicity and treatment burden.